EE200000513A - Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess - Google Patents

Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess

Info

Publication number
EE200000513A
EE200000513A EEP200000513A EEP200000513A EE200000513A EE 200000513 A EE200000513 A EE 200000513A EE P200000513 A EEP200000513 A EE P200000513A EE P200000513 A EEP200000513 A EE P200000513A EE 200000513 A EE200000513 A EE 200000513A
Authority
EE
Estonia
Prior art keywords
preparation
heterocyclic ring
ring systems
containing different
lipoxygenase inhibitors
Prior art date
Application number
EEP200000513A
Other languages
English (en)
Estonian (et)
Inventor
Norris Timothy
Elizabeth Hnatow Megan
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000513A publication Critical patent/EE200000513A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EEP200000513A 1999-08-31 2000-08-31 Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess EE200000513A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
EE200000513A true EE200000513A (et) 2001-04-16

Family

ID=22539510

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000513A EE200000513A (et) 1999-08-31 2000-08-31 Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess

Country Status (33)

Country Link
EP (1) EP1081144A3 (cs)
JP (1) JP2001106686A (cs)
KR (1) KR20010050274A (cs)
CN (1) CN1286251A (cs)
AP (1) AP2000001909A0 (cs)
AR (1) AR022650A1 (cs)
AU (1) AU5370200A (cs)
BG (1) BG104730A (cs)
BR (1) BR0003888A (cs)
CA (1) CA2316748A1 (cs)
CO (1) CO5180623A1 (cs)
CZ (1) CZ20003159A3 (cs)
EA (1) EA200000803A3 (cs)
EE (1) EE200000513A (cs)
GT (1) GT200000144A (cs)
HR (1) HRP20000565A2 (cs)
HU (1) HUP0003437A3 (cs)
ID (1) ID27128A (cs)
IL (1) IL138089A0 (cs)
IS (1) IS5604A (cs)
MA (1) MA26750A1 (cs)
NO (1) NO20004312L (cs)
NZ (1) NZ506633A (cs)
OA (1) OA11451A (cs)
PA (1) PA8499601A1 (cs)
PE (1) PE20010523A1 (cs)
PL (1) PL342280A1 (cs)
SG (1) SG87145A1 (cs)
SK (1) SK12862000A3 (cs)
SV (1) SV2002000160A (cs)
TN (1) TNSN00176A1 (cs)
TR (1) TR200002530A2 (cs)
UY (1) UY26315A1 (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627644A4 (en) * 2003-05-23 2012-01-18 Hisamitsu Pharmaceutical Co PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION WITH AN NON-TEROIDAL INFLAMMATORY MEDICAMENT AND AN INTERLEUKIN 1A PRODUCTION INHIBITOR
EP1834953A1 (en) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
CN103980312B (zh) * 2014-05-27 2016-09-07 广州大学 一种n杂环双膦配体及其合成方法
WO2025038927A1 (en) * 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze

Also Published As

Publication number Publication date
TNSN00176A1 (fr) 2005-11-10
UY26315A1 (es) 2001-04-30
PA8499601A1 (es) 2002-02-21
CO5180623A1 (es) 2002-07-30
SK12862000A3 (sk) 2002-02-05
BG104730A (en) 2001-09-28
EA200000803A2 (ru) 2001-04-23
HUP0003437A2 (hu) 2001-06-28
SG87145A1 (en) 2002-03-19
IS5604A (is) 2001-03-01
MA26750A1 (fr) 2004-12-20
AP2000001909A0 (en) 2000-09-30
JP2001106686A (ja) 2001-04-17
TR200002530A2 (tr) 2001-04-20
OA11451A (en) 2003-12-08
BR0003888A (pt) 2001-12-11
HRP20000565A2 (en) 2001-06-30
KR20010050274A (ko) 2001-06-15
ID27128A (id) 2001-03-01
CZ20003159A3 (cs) 2001-12-12
PL342280A1 (en) 2001-03-12
GT200000144A (es) 2002-02-20
AU5370200A (en) 2001-03-08
CA2316748A1 (en) 2001-02-28
HU0003437D0 (en) 2000-08-30
HUP0003437A3 (en) 2002-08-28
NO20004312D0 (no) 2000-08-30
SV2002000160A (es) 2002-01-23
PE20010523A1 (es) 2001-04-28
EP1081144A3 (en) 2001-04-11
EA200000803A3 (ru) 2001-06-25
AR022650A1 (es) 2002-09-04
NO20004312L (no) 2001-03-01
IL138089A0 (en) 2001-10-31
NZ506633A (en) 2001-12-21
CN1286251A (zh) 2001-03-07
EP1081144A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
NO20025186D0 (no) FremgangsmÕte for syntese av en ecteinascidinforbindelse
EE200200183A (et) Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
IS2223B (is) Aðferð til framleiðslu á 5-sýanóþalíði
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO20013569L (no) Fremgangsmate ved fremstilling av L-fenylephrine-hydroklorid
FI990509A0 (fi) Häiriönpoistomenetelmä
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
EE200000513A (et) Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess
NO20020059L (no) Fremgangsmåte for fremstilling av dibenzotiazepinderivater
NO20013407D0 (no) Fremgangsmåte for fremstilling av kinolinkarbaldehyd
EE200000512A (et) Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess
NO20001985L (no) FremgangsmÕte for forming av strimmelformede folier
NO20013995D0 (no) Fremgangsmate for fremstilling av L-sorbose
NO20024887L (no) FremgangsmÕte for fremstilling av benzokondenserte heterosykliske forbindelser
NO20014383L (no) Fremgangsmåte for fremstilling av syklo-(Asp-DPhe-NMeVal-Arg- Gly)
DE60000817D1 (de) Calixaren-derivate für extraktion von aktiniden
NO20022956L (no) Fremgangsmate for fremstilling av nitroguanidin
NO20000805D0 (no) Fremgangsmåte for fremstilling av organiske azider
IL138088A0 (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
DK1041070T3 (da) Fremgangsmåde til fremstilling af cykliske thioamider
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20021788D0 (no) Fremgangsmåte for fremstilling av ulcerterapeutika
NO20022671D0 (no) Fremgangsmåte for fremstilling av tienopyrimidiner
NO20002558D0 (no) FremgangsmÕte for fremstilling av findisperse eksplosivstoffer